DEF: SelectQuote Reports Strong FY25, Boosts Liquidity

SelectQuote, Inc. announces robust fiscal year 2025 financial results, including significant revenue growth and a strategic capital raise, ahead of its 2025 Annual Meeting of Stockholders.

Summary

• SelectQuote reported total revenue of $1.52 billion for fiscal year 2025, marking an increase of over 15% year-over-year.
• Net income for FY2025 was $47.5 million, with Adjusted EBITDA reaching $126.25 million, surpassing forecasts by more than 20%.
• The company completed a $100 million securitization of commissions receivable, reducing its cost of capital and retaining approximately 85% of its receivables balance.
• A $350 million preferred equity raise from Morgan Stanley Private Credit and Bain Capital Insurance increased liquidity and operational flexibility, while reducing total debt by nearly $300 million.
• The Senior division achieved an Adjusted EBITDA margin of 27%, driven by reduced operating and marketing expenses per policy year-over-year.
• The Healthcare Services division saw revenue growth of over $260 million year-over-year, reaching $743 million, and its Adjusted EBITDA grew by 225% year-over-year, despite modest margin growth.
• A new, state-of-the-art fulfillment facility was opened for the pharmacy business, expanding processing capacity and aiming for continued margin improvement in Healthcare Services.
• The Life division generated $173 million in revenue and increased Adjusted EBITDA by 32% year-over-year.
• The Revenue-to-Customer-Acquisition-Cost multiple for the Senior and Healthcare Services divisions improved to 6.1 in FY2025 from 4.5 in FY2024.
• The Board of Directors unanimously recommends voting FOR the election of two Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor for FY2026, and the non-binding advisory vote on executive compensation.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant revenue and Adjusted EBITDA growth, exceeding forecasts. Strategic capital raises have substantially improved liquidity and reduced debt. While there were some shortfalls in the Healthcare Services division and minor administrative delays in SEC filings, the overall picture is positive, demonstrating effective operational management and strategic execution.

Positives

• Total revenue increased by over 15% year-over-year to $1.52 billion in FY2025.
• Net income for FY2025 was $47.5 million.
• Adjusted EBITDA reached $126.25 million, exceeding forecasts by more than 20%.
• The Senior division achieved a strong Adjusted EBITDA margin of 27% by reducing operating and marketing expenses per policy.
• Healthcare Services division revenue grew by over $260 million year-over-year to $743 million, with Adjusted EBITDA increasing by 225% year-over-year.
• The opening of a new fulfillment facility for the pharmacy business is expected to drive continued margin improvement in Healthcare Services.
• The Life division's revenue was $173 million, and its Adjusted EBITDA increased by 32% year-over-year.
• The Revenue-to-Customer-Acquisition-Cost multiple improved significantly to 6.1 in FY2025 from 4.5 in FY2024.
• A $100 million securitization of commissions receivable reduced the cost of capital and retained approximately 85% of receivables.
• A $350 million preferred equity investment from Morgan Stanley and Bain increased liquidity and operational flexibility, while reducing total debt by nearly $300 million.
• All directors and named executive officers are in compliance with stock ownership guidelines.

Negatives

• The Healthcare Services division fell short of achieving its internal margin growth and EBITDA targets, largely due to external factors like pharmacy network pricing developments.
• Certain Section 16(a) reports for executive officers and a director were filed late due to inadvertent administrative errors.

Risks

• Developments with respect to pharmacy network pricing could continue to impact the Healthcare Services division's margin growth and EBITDA targets.
• Regulatory uncertainty in the Medicare distribution space poses a challenge to the Senior division's performance.

Future Outlook

The company aims to continue driving strong operating efficiency and customer retention in its Senior division, grow Healthcare Services margins and increase divisional EBITDA, and support the expansion of its healthcare services platform through programs like SelectPatient Management and other emerging products. It also plans to increase margins in both Term Life and Final Expense divisions by enhancing technological capabilities and strengthening its sales force. Management will also focus on identifying and executing additional alternatives for paying down term debt, increasing liquidity, and improving operational flexibility.

Management Comments

• Timothy R. Danker, CEO, expressed pleasure in inviting stockholders to the 2025 Annual Meeting and thanked them for their ongoing support and continued interest.
• Management's use of Adjusted EBITDA is to understand and evaluate operating performance, establish budgets, and develop operational goals, believing it provides a useful measure for period-to-period comparisons of core operating performance.

Industry Context

The company operates in the competitive insurance and healthcare services industries, with a growing emphasis on healthcare technology and direct-to-consumer models. Its executive compensation program is designed to attract and retain high-performing executives in this competitive talent market. The expansion of healthcare services and the opening of a new pharmacy fulfillment facility align with broader industry trends towards integrated healthcare solutions and improved operational efficiency.

Comparison to Industry Standards

• The Compensation Committee uses a compensation peer group, including companies like Accolade, Inc., eHealth, Inc., HealthEquity, Inc., and GoHealth, Inc., to assess the competitiveness of executive compensation practices.
• The peer group selection prioritized companies with shared business characteristics, such as pharmacy operations and a direct-to-consumer focus, reflecting the company's strategic direction.
• The company's cumulative total shareholder return is compared against the Center for Research in Security Prices US Small Cap Index (^CRSPSC1) for performance evaluation.

Management Changes

Corporate Governance

Related Party Transactions

• Indemnification agreements have been entered into with each non-executive director and executive officer, providing indemnification for liabilities arising from their service to the fullest extent permitted by Delaware law.
• The Amended and Restated Series D Preferred Stock Investors Rights and Stockholders Agreement, originally from 2014, granted Series D Holders certain rights (e.g., preemptive, director appointment, information, registration). Most rights terminated upon the IPO in May 2020, but certain information and registration rights remain.
• In February 2025, the company entered into Senior Preferred Stock Purchase Agreements with NL Monarch Holdings LLC (Morgan Stanley) and NL Monarch Holdings II LLC (Bain), issuing $350 million in senior non-convertible preferred stock and warrants. These agreements include transfer limitations, a standstill provision, various preemptive rights, and require consent from Morgan Stanley and Bain for a change of control prior to February 28, 2031.
• Director Designation Agreements with Morgan Stanley and Bain allow each purchaser to designate a nominee for election to the Board (Christopher Wolfe for Bain, Srdjan Vukovic for Morgan Stanley) as long as they beneficially own 40% of the preferred stock. Morgan Stanley also has the right to designate a non-voting observer to the Board.

Stakeholder Impact

• Shareholders: Benefit from strong financial performance, increased liquidity, and reduced debt, potentially leading to long-term value creation. Voting rights are exercised at the annual meeting on key proposals including director elections and executive compensation.
• Employees: Benefit from competitive compensation packages, including base salary, annual cash incentives, and equity awards, as well as a 401(k) plan with company matching and potential profit sharing. The expansion of healthcare services may create new opportunities.
• Customers: The growth of the Healthcare Services division and the opening of a new fulfillment facility suggest improved service delivery and expanded offerings, such as the SelectPatient Management program.
• Creditors: The securitization of commissions receivable and the preferred equity raise have reduced total debt and improved the company's financial flexibility, potentially strengthening its credit profile.
• Management and Directors: Compensation is tied to company performance and long-term value creation, with robust stock ownership guidelines aligning their interests with shareholders. New directors from key investors bring additional expertise and oversight.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on November 11, 2025, to elect directors, ratify the independent auditor, and vote on executive compensation.
• Continue to evaluate the company's compensation philosophy to ensure programs evolve with market conditions and company goals.
• Drive continued focus on operational efficiency and customer retention in the Senior division.
• Grow Healthcare Services margins and increase year-over-year divisional EBITDA.
• Support the expansion of the healthcare services platform by increasing enrollments in SelectPatient Management and launching other emerging products.
• Increase margins in both the Term Life and Final Expense divisions by enhancing technological capabilities and strengthening the sales force.
• Identify and execute additional alternatives for paying down term debt, increasing liquidity, and improving operational flexibility.

Key Dates

Recommendation

The filing presents a compelling case for a 'strong buy' recommendation. SelectQuote has demonstrated robust financial performance in FY2025, with significant revenue growth and Adjusted EBITDA exceeding forecasts. The strategic capital raise of $350 million in preferred equity and a $100 million securitization of receivables have substantially improved the company's liquidity, reduced total debt by nearly $300 million, and lowered the cost of capital. These actions provide a strong financial foundation for future growth. Operational efficiencies in the Senior division and impressive growth in the Healthcare Services division, despite some external headwinds, indicate effective management and a strong business model. The improved Revenue-to-Customer-Acquisition-Cost multiple further highlights the efficiency of its platform. While minor administrative delays in SEC filings and some challenges in Healthcare Services margins are noted, the overall strategic direction, financial health, and commitment to shareholder alignment through governance practices (like stock ownership guidelines and a clawback policy) suggest significant upside potential for investors.

Keywords

SelectQuote, SLQT, SEC filing, proxy statement, annual meeting, executive compensation, corporate governance, financial results, revenue, EBITDA, capital raise, preferred equity, insurance, healthcare services, Medicare, stock ownership guidelines, Deloitte & Touche LLP